IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Purchased by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.6% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 20,975 shares of the company’s stock after buying an additional 334 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in IDEXX Laboratories were worth $11,325,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Valley National Advisers Inc. boosted its stake in shares of IDEXX Laboratories by 84.6% in the fourth quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after buying an additional 22 shares in the last quarter. Riverview Trust Co acquired a new position in shares of IDEXX Laboratories during the 1st quarter worth $26,000. OFI Invest Asset Management acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth $25,000. DSM Capital Partners LLC acquired a new stake in IDEXX Laboratories in the 4th quarter valued at about $33,000. Finally, Private Wealth Management Group LLC acquired a new stake in IDEXX Laboratories in the 4th quarter valued at about $34,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on IDXX. The Goldman Sachs Group upped their price target on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. JPMorgan Chase & Co. raised their price target on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Thursday. Barclays decreased their price objective on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research note on Thursday. Finally, Piper Sandler lowered shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price on the stock. in a report on Tuesday, January 30th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $580.88.

IDEXX Laboratories Trading Up 1.0 %

Shares of IDXX stock traded up $4.78 during trading hours on Friday, hitting $480.60. 547,954 shares of the company were exchanged, compared to its average volume of 509,434. The firm has a fifty day moving average of $523.29 and a 200 day moving average of $512.43. The company has a quick ratio of 1.17, a current ratio of 1.57 and a debt-to-equity ratio of 0.40. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39. The firm has a market cap of $39.69 billion, a PE ratio of 46.52, a PEG ratio of 3.74 and a beta of 1.27.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, topping analysts’ consensus estimates of $2.12 by $0.20. The company had revenue of $901.60 million for the quarter, compared to the consensus estimate of $891.88 million. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. IDEXX Laboratories’s revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.05 earnings per share. Analysts expect that IDEXX Laboratories, Inc. will post 11.06 earnings per share for the current year.

Insider Activity at IDEXX Laboratories

In related news, SVP George Fennell sold 8,198 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the sale, the senior vice president now directly owns 6,712 shares in the company, valued at approximately $3,851,815.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other IDEXX Laboratories news, CFO Brian P. Mckeon sold 23,326 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total value of $13,296,053.26. Following the completion of the transaction, the chief financial officer now directly owns 29,718 shares of the company’s stock, valued at approximately $16,939,557.18. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP George Fennell sold 8,198 shares of the firm’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $573.87, for a total value of $4,704,586.26. Following the sale, the senior vice president now owns 6,712 shares of the company’s stock, valued at $3,851,815.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 43,524 shares of company stock worth $24,871,960. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.